ASH: Af­ter a pi­lot study of­fers a glimpse of hope for Tes­sa's CD30-tar­get­ing CAR-T, ex­ecs sprint to­ward a piv­otal tri­al

CAR-Ts tar­get­ing CD19 — like Yescar­ta, Kym­ri­ah and the re­cent­ly ap­proved Breyanzi — have shift­ed the par­a­digm for the treat­ment of B cell lym­phoma, ac­cord­ing to Sairah Ahmed, a long­time re­searcher in the field. Now, as prin­ci­pal in­ves­ti­ga­tor, she’s lead­ing ef­forts to see if Tes­sa Ther­a­peu­tics’ CD30-tar­get­ing CAR-T can do the same for pa­tients with clas­si­cal Hodgkin lym­phoma (cHL).

More than half of the pa­tients who took Tes­sa’s can­di­date TT11 in the pi­lot stage of a Phase II study saw their can­cer dis­ap­pear, the com­pa­ny said at this year’s ASH con­fer­ence. Of 15 heav­i­ly pre-treat­ed pa­tients with re­lapsed or re­frac­to­ry CD30-pos­i­tive cHL, 11 saw dis­ease con­trol at the da­ta cut off, in­clud­ing eight com­plete re­spons­es, two par­tial re­spons­es and one case of sta­ble dis­ease, ac­cord­ing to re­searchers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER